Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ethan A. Burns"'
Autor:
Ethan A. Burns, MD, Wan Hsiang Chen, MD, Sunil Mathur, PhD, Ryan B. Kieser, MD, Jun Zhang, MD, Eric H. Bernicker, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100570- (2023)
Introduction: The aim of this study is to evaluate treatment patterns, survival outcomes, and factors influencing systemic treatment decisions in adults 80 years and older with NSCLC. Methods: This was a retrospective National Cancer Database study e
Externí odkaz:
https://doaj.org/article/c04c1d846308430fa535fb49bf5ec2a7
Autor:
Charisma Mylavarapu, Alexander J. Lu, Ethan A. Burns, Justin Samorajski, Deepa Gotur, Kelty Baker
Publikováno v:
Case Reports in Medicine, Vol 2022 (2022)
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disease characterized by the formation of cutaneous and visceral telangiectasias and arteriovenous malformations (AVM). Multiple organs may be affected, including the nasal
Externí odkaz:
https://doaj.org/article/8730cff59f0942d5920f4b20a11f1efd
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Histiocytic sarcoma (HS) is an uncommon malignant neoplasm arising from mature histiocytes and most commonly characterized by the immunophenotypic expression of CD68, CD163, or lysozyme. Although rare, HS arising as a second primary malignancy follow
Externí odkaz:
https://doaj.org/article/826ba486d756441699a618ec0118c436
Publikováno v:
Diseases, Vol 9, Iss 1, p 20 (2021)
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized,
Externí odkaz:
https://doaj.org/article/1ad5118f2fee4258b5bd9ec739f88efb
Autor:
Ethan A. Burns, Cesar Gentille Sanchez, Sunil Mathur, Carlo Guerrero, Ibrahim N. Muhsen, Humaira Sarfraz, Chih-Chi Andrew Hu, Chih-Hang Anthony Tang, Shilpan S. Shah, Ivo W. Tremont, Bin Teh, Siddhartha Ganguly, Sai Ravi Kiran Pingali
Publikováno v:
Annals of Hematology. 102:1111-1120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::768302d853775dcbfe2b3b0baa384869
https://doi.org/10.1007/s00277-023-05140-6
https://doi.org/10.1007/s00277-023-05140-6
Publikováno v:
Current Oncology Reports. 24:475-491
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::637ccf85221b4a51989fc7636cd17eef
https://doi.org/10.1007/s11912-022-01215-1
https://doi.org/10.1007/s11912-022-01215-1
Autor:
Ethan A. Burns, Sunil Mathur, Darshil Choksi, Hala Hassanain, Yuqi Zhang, Cesar Gentille Sanchez, Ryan B. Kieser, Carrie Yuen, Shilpan S. Shah, Siddhartha Ganguly, Sai Ravi Kiran Pingali
Publikováno v:
Blood. 140:3687-3688
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed417b34dbfb1626f75cf39a162e898f
https://doi.org/10.1182/blood-2022-159777
https://doi.org/10.1182/blood-2022-159777
Publikováno v:
Current oncology reportsPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance. 24(4)
Tyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) have changed the therapeutic landscape across a range of solid malignancies. However, there is little data regarding the cardiov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15410e9b6b3a6e2a213a7b12dd3be00f
https://pubmed.ncbi.nlm.nih.gov/35192115
https://pubmed.ncbi.nlm.nih.gov/35192115
Autor:
Ethan A. Burns, Kelly Gee, Ryan B. Kieser, Jiaqiong Xu, Yuqi Zhang, Aubrey Crenshaw, Ibrahim N. Muhsen, Charisma Mylavarapu, Abdullah Esmail, Shivan Shah, Godsfavour Umoru, Kai Sun, Carlo Guerrero, Zimu Gong, Kirk Heyne, Monisha Singh, Jun Zhang, Eric H. Bernicker, Maen Abdelrahim
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 81
Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved outcomes across a range of malignancies. While infections are a well-known contributor to morbidity and mortality amongst patients receiving systemic chemotherapy regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bcaf9052479bd454701a53116cd9659
https://doi.org/10.3390/cancers15010081
https://doi.org/10.3390/cancers15010081
Autor:
Syeda A., Mina, Ibrahim N., Muhsen, Ethan A., Burns, Humaira, Sarfraz, Sai Ravi, Pingali, Jiaqiong, Xu, Shahrukh K., Hashmi
Publikováno v:
Turkish Journal of Hematology
Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-knownconsequence of PIs, most frequently reported with earlier generations such as bortezomib (BTZ). There is a paucity of data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ab7e793927f8c9457a187dfb40c6ef08
https://pubmed.ncbi.nlm.nih.gov/34190655
https://pubmed.ncbi.nlm.nih.gov/34190655